Detection of Lung Cancer by Plasma Lipids

Completed

• Conditions: Early-Stage Lung Cancer
• Interventions: Diagnostic Test: Plasma lipids

• Registration Number: NCT04287712
• Lead Sponsor: Peking University People's Hospital

Brief Summary

There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Detailed Description

All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Study Timeline

• Study Start: 2018-12-13
• Primary Completion: 2019-10-31
• Study First Submitted: 2020-02-13
• Study First Submitted QC: 2020-02-25
• Study First Posted: 2020-02-27
• Study Completion: 2020-05-20
• Status Verified: 2020-06
• Last Update Submitted: 2020-06-02
• Last Update Posted: 2020-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 558

Inclusion Criteria

1. pulmonary nodules or opacity
2. plan to receive surgery

Exclusion Criteria

1. history of other malignancies
2. received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants received surgery	Plasma lipids	Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.

Primary Outcome Measures

Name	Time	Method
Plasma Lipids	All samples were detected together after participants recruitment and sample collection. All samples were detected within 18 months from sample collection.	A detection model based on 9 lipids were developed, including 3 lysophosphatidylcholines, 5 phosphatidylcholines, and a triglyceride. The 9 lipids were detected by targeted metabolomics by mass spectrometry.

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China